News NICE says no to Ipsen’s kidney cancer drug NICE has issued draft guidance which rejects Ipsen's Cabometyx for NHS use in previously treated advanced renal cell carcinoma (RCC).
News Merrimack goes back to drawing board with $1bn Ipsen sell-of... Merrimack sells off Onivyde and generic cancer drug
News Ipsen/Exelixis' drug approved in EU for kidney cancer Cabometyx secures new indication in renal cell carcinoma.
Views & Analysis Ipsen: future of healthcare is digital – but some at risk of... Risk of a 'two speed' healthcare because of digital inequality
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
